Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

5.360 -0.290 (-5.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
The Latest Analyst Ratings for Coya Therapeutics ↗
 
Via Benzinga
News headline image
Coya Therapeutics: Another Sucess ↗
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. 
Via Talk Markets
News headline image
Why Coya Therapeutics Shares Are Shooting Higher Today ↗
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in  
Via Benzinga
News headline image
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Via Get News
News headline image
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... 
Via Benzinga
News headline image
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation ↗
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
News headline image
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗
 
Via Benzinga
News headline image
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Positive Financials Along With Promising Clinical Results – Coya Therapeutics ↗
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023 ↗
 
Via Benzinga
News headline image
Coya Therapeutics: An Attractive Valuation And First Set Of Data ↗
Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions. 
Via Talk Markets
News headline image
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
Via ACCESSWIRE
News headline image
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer? ↗
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.